Baxi Shrujal S, Schwitzer Emily, Jones Lee W
1Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Rm 1459, New York, NY 10065 USA.
2Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 USA.
Cancers Head Neck. 2016 Aug 17;1:9. doi: 10.1186/s41199-016-0010-0. eCollection 2016.
Concurrent chemotherapy and radiation (CTRT) improves disease-free survival in locally advanced head and neck cancer but is associated with numerous acute and chronic toxicities resulting in substantial alterations in body mass and composition. We aim to summarize the current evidence on body composition changes experienced by patients undergoing CTRT, examine the impact of these changes on clinical outcomes and address potential interventions aimed at mitigating the loss.
Loss of 20 % of pre-CTRT weight predicts poorer treatment tolerance and 30-day mortality. While clinical practice focuses on body weight, emerging data indicates that CTRT causes profound adverse changes in lean body mass (sarcopenia). Higher prevalence of sarcopenia predicts poorer disease-free survival as well as overall survival, lower quality of life and functional performance. The magnitude of CTRT-induced sarcopenia is the equivalent to that observed in a decade of aging in a healthy adult. Alterations in body composition are only explained, in part, by decreased caloric intake; other significant predictors include body mass index, stage, and dysphagia. Lifestyle interventions aimed at preventing loss of whole-body and especially lean mass include nutritional counseling, nutritional supplements, dietary supplements and exercise training. Personalized nutritional counseling has been associated with improvement in quality of life, while the benefits of feeding tube placement are inconsistent. There are inconsistently reported benefits of resistance training in this population.
Patients with head and neck cancer undergoing CTRT therapy experience dramatic shifts in body composition, including sarcopenia, which can negatively impact clinical outcomes. Efforts to understand the magnitude, clinical importance and mechanisms of sarcopenia are needed to inform a more personalized approach to mitigating the body composition changes associated with CTRT.
同步放化疗(CTRT)可提高局部晚期头颈癌患者的无病生存率,但会引发多种急慢性毒性反应,导致体重和身体成分发生显著变化。我们旨在总结接受CTRT治疗的患者身体成分变化的现有证据,研究这些变化对临床结局的影响,并探讨旨在减轻体重减轻的潜在干预措施。
CTRT治疗前体重减轻20%预示着较差的治疗耐受性和30天死亡率。虽然临床实践主要关注体重,但新出现的数据表明,CTRT会导致瘦体重(肌肉减少症)发生严重的不良变化。肌肉减少症的患病率较高预示着无病生存率和总生存率较低、生活质量和功能表现较差。CTRT引起的肌肉减少症的程度与健康成年人十年衰老过程中观察到的程度相当。身体成分的变化仅部分由热量摄入减少来解释;其他重要的预测因素包括体重指数、分期和吞咽困难。旨在预防全身尤其是瘦体重流失的生活方式干预措施包括营养咨询、营养补充剂、膳食补充剂和运动训练。个性化营养咨询与生活质量的改善有关,而放置鼻饲管的益处并不一致。关于该人群进行抗阻训练的益处,报道并不一致。
接受CTRT治疗的头颈癌患者身体成分会发生显著变化,包括肌肉减少症,这可能会对临床结局产生负面影响。需要努力了解肌肉减少症的程度、临床重要性和机制,以便采取更个性化的方法来减轻与CTRT相关的身体成分变化。